Compare ARE & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | STVN |
|---|---|---|
| Founded | 1994 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Containers/Packaging |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.4B |
| IPO Year | 1997 | 2021 |
| Metric | ARE | STVN |
|---|---|---|
| Price | $47.14 | $21.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $69.38 | $25.38 |
| AVG Volume (30 Days) | ★ 3.1M | 338.7K |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 10.03% | 0.30% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $3,058,395,000.00 | $1,373,219,524.00 |
| Revenue This Year | N/A | $8.42 |
| Revenue Next Year | N/A | $9.52 |
| P/E Ratio | ★ N/A | $34.83 |
| Revenue Growth | N/A | ★ 6.97 |
| 52 Week Low | $44.10 | $17.81 |
| 52 Week High | $105.14 | $28.00 |
| Indicator | ARE | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 39.50 |
| Support Level | $44.10 | $20.50 |
| Resistance Level | $47.19 | $22.29 |
| Average True Range (ATR) | 1.68 | 1.09 |
| MACD | 0.40 | -0.08 |
| Stochastic Oscillator | 28.91 | 12.23 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.